The Healthcare Sub-Sector Map: How Bankers Think About the Industry

Introduction

When an interviewer asks you to discuss a healthcare company, the first thing they are testing is whether you can place it in the right sub-sector and explain why that classification matters. A biotech company and a healthcare services company may both fall under "healthcare," but they have almost nothing in common analytically. The business models, valuation methods, M&A drivers, and risk profiles are fundamentally different. Knowing the work healthcare bankers do is the first step; knowing how the industry is organized is the second.

This article maps the five major sub-sectors as healthcare bankers define them, explains what makes each one distinct, and covers where emerging categories like healthcare IT and digital health fit into the framework.

Healthcare bankers organize the industry into five distinct verticals. Each has its own business model archetype, preferred valuation method, and dominant transaction type. The table below provides the high-level comparison; the sections that follow explain what drives these differences.

Pharmaceuticals

Big Pharma companies (Pfizer, J&J, Merck, Novartis, Roche, AbbVie) are diversified, profitable, and cash-generative. They discover or acquire drugs, protect them through patents and regulatory exclusivity, and commercialize them through global sales forces. The defining analytical challenge is the patent cliff: every branded drug has a known expiration date after which revenue drops 80-90% as generics enter. This makes pharma the only sector where you can see billions in revenue destruction years in advance, and it is the primary driver of pharma M&A.

Pharma companies are best valued using sum-of-the-parts (SOTP): each commercial product gets its own DCF through its loss of exclusivity date, pipeline assets get probability-weighted valuations, and the pieces sum to enterprise value. A single EV/EBITDA multiple is misleading because the earnings profile will look fundamentally different in five years.

Biotech

Biotech companies range from pre-revenue clinical-stage startups to large commercial biotechs like Amgen, Gilead, and Regeneron. The distinguishing feature is pipeline dependency: a clinical-stage biotech's entire value is derived from drugs that have not yet been approved. Financial statements are inverted, with rising R&D spending and widening losses signaling progress rather than deterioration.

Cash Runway

The number of months a pre-revenue biotech can continue operating at its current burn rate before needing additional capital. Calculated as cash and equivalents divided by quarterly cash burn. A company with $200 million in cash burning $25 million per quarter has a 24-month runway. This is often the most important near-term metric for clinical-stage biotechs.

Valuation centers on risk-adjusted NPV (rNPV), which probability-weights future cash flows by clinical success rates at each development phase. Standard DCF does not apply because it cannot properly capture the binary risk of clinical trial outcomes. The overall probability of a drug reaching approval from Phase I is roughly 10-14%, but this varies dramatically by therapeutic area and modality.

Medical Devices and MedTech

The medical device sector operates on a razor/blade business model. Companies sell instruments or capital equipment (the "razor") at moderate margins, then generate decades of high-margin consumable and service revenue (the "blades"). Intuitive Surgical's installed base of over 10,000 da Vinci systems generates billions in recurring instrument and accessory revenue per year.

Revenue is modeled as Procedures x Devices per Procedure x Average Selling Price (ASP). Each variable has distinct drivers: procedure volumes are driven by demographics and clinical adoption, while ASP faces structural erosion of 2-4% annually from hospital purchasing pressure and competitor entry. Valuation uses EV/Revenue for high-growth companies and EV/EBITDA for mature ones, with regulatory pathway (510(k) vs. PMA) influencing competitive moat assessment.

Healthcare Services

Healthcare services is the most active sub-sector for PE deal activity, driven by extreme market fragmentation. The US has over 900,000 physician practices, most with fewer than 10 providers. This creates a textbook consolidation opportunity: PE firms acquire a management platform at 5-7x EBITDA, bolt on smaller practices at 3-5x, centralize operations, and exit the combined entity at 9-12x or higher.

The key financial metric is payer mix: the percentage of revenue from commercial insurance vs. government programs (Medicare, Medicaid). Commercial payers reimburse at rates 2-4x higher than government programs, so a company with 70% commercial payer mix will have dramatically higher margins than one with 70% government payer mix, even if total patient volumes are identical.

Life Sciences Tools and Diagnostics

The life sciences tools sector serves the companies in the other four sub-sectors. CROs (contract research organizations) run clinical trials for pharma and biotech clients. CDMOs (contract development and manufacturing organizations) manufacture drug products. Tools companies (Thermo Fisher, Danaher, Agilent) sell instruments, reagents, and consumables used in R&D labs. Diagnostics companies develop tests for disease detection.

Book-to-Bill Ratio

The ratio of new contract bookings to revenue recognized in a given period. A book-to-bill above 1.0x means the company is adding backlog faster than it is working through it, indicating growing demand. This is the most closely watched metric for CROs and CDMOs, where large multi-year contracts create significant backlog visibility.

The business model premium in tools comes from recurring revenue. A CRO with multi-year clinical trial contracts or a tools company where 80% of revenue comes from consumable refills commands a significantly higher multiple than a capital equipment company with lumpy, one-time sales. Valuations of 15-25x EBITDA are common for high-recurring-revenue tools companies, reflecting the predictability and durability of their earnings.

Healthcare IT (HCIT) and digital health do not form a sixth standalone sub-sector in most banking organizations. Instead, they sit at the intersection of healthcare and technology, and banks handle them differently depending on their size and structure.

HCIT companies include electronic health record (EHR) platforms, revenue cycle management software, telehealth platforms, and AI-enabled clinical tools. Dealmaking in HCIT reached four-year highs in both volume and value in 2025, driven by AI and GenAI adoption in clinical documentation, diagnostics, and administrative workflows. Analytically, these companies are valued more like software businesses (EV/Revenue, Rule of 40) than traditional healthcare companies, but their end-market dynamics require healthcare domain knowledge.

Each sub-sector has its own body of specialized knowledge, and healthcare interviews often test whether you understand the sub-sector relevant to the group's coverage focus. A banker interviewing for a pharma/biotech-focused team will face questions about rNPV methodology, clinical trial phases, and FDA pathways. A banker interviewing for a services-focused team will face questions about payer mix, roll-up economics, and provider reimbursement.

The remaining sections of this guide dive deep into each sub-sector, starting with the cross-cutting fundamentals (regulatory, reimbursement, and valuation foundations) that apply everywhere, then progressing through dedicated sections on pharma, biotech, medtech, services, and life sciences tools.